Newsfeeds - Spark Newswire

3 minute read

World Class Leaders In Psychedelics Form Benzinga’s Psychedelic Advisory Council—Get To Know Them

Today, 8:48 PM

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.

ATAI

5 minute read

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill

By Natan Ponieman

Today, 8:48 PM

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.

CSE:ENBI

2 minute read

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

By Lara Goldstein

Today, 8:48 PM

Ehave, Inc. (OTC Pink: EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health.

EHVVF

1 minute read

Entheon Biomedical Announces Non-Brokered Private Placement Financing

By Fermin Orgambide

Today, 8:48 PM

Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10…

ENTBF

2 minute read

Benzinga’s Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th

By Benzinga Cannabis

Today, 8:48 PM

The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022, in Miami, Florida.

CSE:ENBI

5 minute read

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins

By Natan Ponieman

Today, 8:48 PM

The Week in Psychedelics

CYBN

2 minute read

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca’s Active Ingredient

By Natan Ponieman

Today, 8:48 PM

Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT.

CSE:ENBI